Opinion on Respiratory in United Kingdom

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Nycomed/Merck: Daxas deal will have limited financial impact

Nycomed and Merck & Co. have agreed to co-promote the novel COPD therapy Daxas, which recently gained a positive recommendation in the EU. While this collaboration boosts Daxas' commercial prospects in several European countries, as well as Canada, the drug is limited by its restricted patient potential.

Published By Datamonitor
28 Apr 2010
CommentWire
CommentWire

GlaxoSmithKline: will novel device convince physicians?

GlaxoSmithKline has reported positive results for Veramyst nasal spray in the treatment of allergy symptoms for patients 12 years and older with perennial allergic rhinitis. Although the positive data will help sales, commercial success will also depend on how well its novel device can convince physicians to switch patients over from rival products with similar pharmacological properties.

Published By Datamonitor
14 Nov 2007
CommentWire
CommentWire

SkyePharma: Flutiform back on track

Under a newly signed agreement, Kos Pharmaceuticals will have exclusive rights to market SkyePharma's Flutiform for adult and adolescent asthma in the US and possibly Canada. The US company will also be responsible for potential clinical development in COPD and pediatric asthma. Following a period of uncertainty over its future, with this deal Flutiform now seems on track for a US launch in 2009.

Published By Datamonitor
09 May 2006
CommentWire
CommentWire

Asthma and eczema: gene discovery could be the missing link

University of Dundee researchers have discovered a new gene that, when mutated, causes eczema and may be associated with asthma. An estimated 10% of the European population carries this mutation, sometimes leading to severe, uncontrolled disease requiring specialist treatment. However, while the discovery holds promise for new treatments for these patients, these drugs are still a long way off.

Published By Datamonitor
23 Mar 2006
ResearchWire
ResearchWire

Asthma: two-thirds of patients suffer persistently

Published By Datamonitor
15 Apr 2005
CommentWire
CommentWire

GlaxoSmithKline: breathe easy

According to their recently signed strategic alliance GSK [GSK.L] has exercised its option to license Theravance's promising respiratory program. Such alliances with smaller biopharma companies offer a fruitful means for the big players like GSK to broaden their portfolio of new drugs, and deals such as this are likely to become more common in future.

Published By Datamonitor
22 Mar 2005
Expert View
Expert View

Serevent warning focuses attention on the need for combination therapy

The recent announcement by the FDA's associate director for science and medicine that sales of GlaxoSmithKline's asthma drug Serevent should be restricted, or halted, led to an estimated 3.8% fall in the company's share price. However, Datamonitor's Laura Harris comments that, with Seretide accounting for the majority of GSK's asthma sales, the panic may be premature.

Published By Datamonitor
23 Nov 2004
Expert View
Expert View

Double trouble hits Altana respiratory pipeline

Altana has announced the delay of its US application for Daxas until late 2005 due to clinical trial enrolment taking longer than originally anticipated. The news will be of further concern to the company's investors, coming on the back of the recent announcement that another of its respiratory drugs, Alvesco, failed to win full FDA approval.

Published By Datamonitor
02 Nov 2004
CommentWire
CommentWire

GSK: asthma hospitalizations and healthcare costs reduced by Advair

A new study shows that asthma patients taking Advair have a 71% lower risk of an emergency department visit or hospitalization, and 11% lower asthma related healthcare costs, than patients taking the same treatments from separate inhalers. These results underline the gold standard status of Advair in asthma, and represent a persuasive argument from GSK in favor of its lead product.

Published By Datamonitor
29 Mar 2004
CommentWire
CommentWire

GSK: Advair faces patent challenge

GlaxoSmithKline's [GSK.L] sales-leading drug Advair (Seretide in Europe) is being challenged on the validity of a key patent in the UK, with a ruling expected in the next two months. The potential loss of sales in the UK is significant and an unfavorable ruling could lead to further patent challenges.

Published By Datamonitor
15 Mar 2004

« | 1 | 2 | » »|

No help is available.